Cumulative incidence of CMV infection in the first 270 days after HCT. The cumulative incidence of CMV infection from days 0 through 270 after HCT in letermovir recipients and controls with preemptive treatment. A positive viral event was defined as a composite of CMV end-organ disease or CMV PCR DNAemia: at any level, ≥150 IU/mL, or ≥500 IU/mL for the assay used. Death was treated as a competing risk. Note that only a proportion of patients in both groups had late (after post-HCT day 100) CMV DNA PCR results available for analysis (36 letermovir recipients, 75 controls). Patients without late CMV DNA PCR surveillance were censored only if they did not have late CMV disease data available via review of the electronic medical record or our long-term follow-up database.